Zengbin Wang | Chemotherapy | Best Researcher Award

Posted on 26/03/202526/03/2025 by Pencis

Assoc. Prof. Dr. Zengbin Wang | Chemotherapy | Best Researcher Award

Fujian Medical University | China

AUTHOR PROFILE

📝 CURRICULUM VITAE – ZENGBIN WANG, PhD

🎓 EARLY ACADEMIC PURSUITS

Zengbin Wang began his academic journey with a strong foundation in medical sciences. He earned his Master of Medicine in Immunology from Fujian Medical University (Sep 2017 – Jun 2020), where he cultivated his expertise in immune responses and disease mechanisms. Subsequently, he pursued and completed his Doctor of Medicine (MD) in Clinical Laboratory Diagnostics at the same institution (Sep 2020 – Jun 2023). During his doctoral studies, he focused on laboratory-based diagnostics, exploring molecular pathways and immune responses in various diseases, laying the groundwork for his future research contributions.

👩‍🏫 PROFESSIONAL ENDEAVORS

Since September 4, 2023, Zengbin Wang has been serving as a lecturer at the Department of Immunology, School of Basic Medical Sciences, Fujian Medical University. In this role, he actively contributes to both academic instruction and research mentorship. His teaching focuses on immunology, molecular diagnostics, and clinical laboratory techniques. His position also involves supervising student research projects, fostering scientific inquiry, and guiding the next generation of medical scientists.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CHEMOTHERAPY

Zengbin Wang’s research interests span multiple fields in oncology and immunology, with a primary focus on:

DILI (Drug-Induced Liver Injury): Investigating the molecular mechanisms of hepatotoxicity caused by pharmaceuticals.
Arsenic-Induced Lung Cancer: Exploring the oncogenic pathways and cellular responses triggered by arsenic exposure.
Signal Regulation and Autophagy: Studying the complex signaling cascades and autophagic processes in cancer progression.
SUMOylation and Acetylation: Delving into post-translational modifications and their impact on tumorigenesis.
Tumor Immunity: Examining immune responses in the tumor microenvironment, with a focus on immune evasion and therapeutic targeting.

📚 IMPACT AND INFLUENCE

In the past three years, Dr. Wang has demonstrated remarkable productivity and influence in his field, having published 13 SCI-indexed papers as the first author in prestigious journals, including:

🧬 Science Signaling
🧫 Cellular Oncology
🔬 Cell Communication and Signaling
💊 Biomedicine & Pharmacotherapy
☣️ Toxicology
🔗 Communications Biology
⚕️ Toxicology and Applied Pharmacology

His research has contributed to advancing the understanding of cancer biology, autophagy, and tumor immunity, providing valuable insights into the molecular underpinnings of disease progression and potential therapeutic interventions.

🔥 ACADEMIC CITES AND FUNDING ACHIEVEMENTS

Dr. Wang’s research accomplishments are further underscored by his involvement in several high-profile projects, including:

Startup Fund for Scientific Research of Fujian Medical University (2019QH2022) – Principal Investigator.
National Natural Science Foundation of China (82403155) – Lead Investigator.
Key Project of Fujian Provincial Natural Science Foundation (2022J02039) – Second person in charge.
National Natural Science Foundation of China (82173167) – Key participant.

These projects reflect his ability to secure competitive funding, demonstrating his expertise in developing and leading impactful research initiatives.

🌍 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Zengbin Wang's legacy is marked by his prolific scientific output, impactful discoveries, and commitment to advancing oncology and immunology research. His work on SUMOylation, acetylation, and tumor immunity holds significant potential for influencing cancer treatment strategies, particularly in the development of novel immunotherapies and diagnostic tools.

Looking forward, Dr. Wang aims to:

Expand his research on post-translational modifications and their role in tumor progression.
Collaborate with international researchers to broaden the clinical applications of his findings.
Mentor the next generation of scientists, fostering innovation and scientific excellence in oncology and immunology.

🛡️ CONCLUSION

Dr. Zengbin Wang is an influential figure in oncology, immunology, and molecular diagnostics, recognized for his substantial research output, leadership in major projects, and dedication to scientific advancement. With a proven track record of impactful publications and research funding, he is poised to make significant contributions to cancer research and therapeutic development, enhancing the scientific community's understanding of disease mechanisms and treatment approaches.

📊🔬NOTABLE PUBLICATION:

- Title: 2,5-Dimethylcelecoxib Alleviated NK and T-Cell Exhaustion in Hepatocellular Carcinoma via the Gastrointestinal Microbiota-AMPK-mTOR Axis
  - Authors: Pan, B.; Chen, Z.; Zhang, X.; Wang, Z.; Yao, Y.; Wu, X.; Qiu, J.; Lin, H.; Yu, L.; Tu, H.
  - Journal: Journal for ImmunoTherapy of Cancer
  - Year: 2023
- Title: Targeted Inhibition of RBPJ Transcription Complex Alleviates the Exhaustion of CD8⁺ T Cells in Hepatocellular Carcinoma (Erratum: Author Correction)
  - Authors: Pan, B.; Wang, Z.; Zhang, X.; Shen, S.; Ke, X.; Qiu, J.; Yao, Y.; Wu, X.; Wang, X.; Tang, N.
  - Journal: Communications Biology
  - Year: 2023
- Title: IL-33/ST2 Antagonizes STING Signal Transduction via Autophagy in Response to Acetaminophen-Mediated Toxicological Immunity
  - Authors: Wang, Z.; Sun, P.; Pan, B.; Qiu, J.; Zhang, X.; Shen, S.; Ke, X.; Tang, N.
  - Journal: Cell Communication and Signaling
  - Year: 2023
- Title: SUMOylation Inhibitors Activate Anti-Tumor Immunity by Reshaping the Immune Microenvironment in a Preclinical Model of Hepatocellular Carcinoma
  - Authors: Wang, Z.; Pan, B.; Su, L.; Yu, H.; Wu, X.; Yao, Y.; Zhang, X.; Qiu, J.; Tang, N.
  - Journal: Cellular Oncology
  - Year: 2023
- Title: Targeted Inhibition of RBPJ Transcription Complex Alleviates the Exhaustion of CD8⁺ T Cells in Hepatocellular Carcinoma
  - Authors: Pan, B.; Wang, Z.; Zhang, X.; Shen, S.; Ke, X.; Qiu, J.; Yao, Y.; Wu, X.; Wang, X.; Tang, N.
  - Journal: Communications Biology
  - Year: 2023

Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Posted on 24/03/202524/03/2025 by Pencis

Prof. Dr. Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Harbin Normal University | China

AUTHOR PROFILE

Scopus

🧑‍🏫 YINGXUE JIN – PROFESSIONAL PROFILE

🎓 EARLY ACADEMIC PURSUITS

Yingxue Jin embarked on his academic journey with a strong foundation in science, eventually earning a Doctor of Science degree from Pusan National University in Korea in 2003. His academic background laid the groundwork for his expertise in pharmaceutical engineering and drug design. During his doctoral studies, he specialized in small molecule cyclic peptide drugs and nanodrug delivery systems, establishing a solid base for his future research contributions.

💼 PROFESSIONAL ENDEAVORS

Yingxue Jin has accumulated over three decades of experience in academia and research, holding key positions in prestigious institutions and companies:

Professor at Jiamusi University (1990 – 1999): Contributed to teaching and research in pharmaceutical sciences.
Senior Researcher at Korea Ilshin Chemical Company (2003 – 2004): Engaged in advanced chemical research, expanding his expertise in molecular synthesis.
Postdoctoral Researcher at Taiwan University, China (2005 – 2006): Conducted postdoctoral studies, refining his knowledge in pharmaceutical engineering and drug delivery mechanisms.
Professor at Harbin Normal University, China (2006 – Present):
- Serving as Head of the Department of Pharmaceutical Engineering.
- Director of Heilongjiang Chemical Society of China, promoting chemical science advancements.
- Awarded the honorary title of “Famous Teacher” at Harbin Normal University, recognizing his excellence in education and mentorship.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACO-ONCOLOGY

Yingxue Jin’s primary research interests revolve around:

Design and Synthesis of Small Molecule Cyclic Peptide Drugs: Developing novel peptide-based therapeutic agents for various diseases, including cancer.
Anti-Tumor Nanodrug Delivery Systems: Innovating targeted drug delivery methods to enhance the efficacy and precision of cancer treatments.
Project Leadership:
- Presided over two projects funded by the Natural Science Foundation of China (NSFC).
- Led the implementation of one key project and two general projects under the Natural Science Foundation of Heilongjiang Province, China.
- Supervised three natural science projects for the Heilongjiang Provincial Education Department, China.

🏅 IMPACT AND INFLUENCE

Yingxue Jin’s impactful contributions have been widely recognized through multiple awards and honors:

Natural Science and Technology Award of Heilongjiang Province: Acknowledging his significant scientific achievements.
Science and Technology Award of Heilongjiang Provincial Education Department: Recognizing his contributions to technological advancements in education.
Teaching Quality Award at Harbin Normal University (Multiple Occasions): Honoring his dedication to educational excellence and mentorship.

📚 ACADEMIC CITATIONS

Throughout his career, Yingxue Jin’s research has been widely cited in scientific publications, reflecting the influence and relevance of his work in the fields of pharmaceutical sciences, chemical engineering, and nanomedicine. His contributions have been referenced in numerous peer-reviewed journals, further establishing his reputation as a leading researcher in his field.

🌍 LEGACY AND FUTURE CONTRIBUTIONS

Yingxue Jin’s legacy is marked by his dedication to scientific innovation, educational mentorship, and pharmaceutical advancements. Moving forward, he aims to:

Expand his research in nanodrug delivery systems, focusing on precision medicine for oncology applications.
Foster collaborations with international research institutions to drive cross-disciplinary advancements.
Continue mentoring the next generation of scientists, contributing to the development of future leaders in pharmaceutical sciences.

🛡️ KEY ACHIEVEMENTS AND RECOGNITION

Honorary Title: Famous Teacher of Harbin Normal University.
Leadership Roles: Head of the Department of Pharmaceutical Engineering and Director of Heilongjiang Chemical Society of China.
Award-Winning Scientist: Recipient of multiple science and technology awards.
Renowned Educator: Consistently recognized for outstanding teaching quality.

🚀 CONCLUSION

Yingxue Jin’s extensive experience, innovative research, and dedication to scientific excellence and education have positioned him as a distinguished figure in the field of pharmaceutical sciences. His continued contributions to nanodrug delivery systems and cyclic peptide drug design are paving the way for groundbreaking advancements in cancer treatment and precision medicine.

📊🔬NOTABLE PUBLICATION:

1️⃣ Exploring the Potential of Cyclic Peptidyl Antitumor Agents Derived from Natural Macrocyclic Peptide Phakellistatin 13

Authors: Tong T. Li, Shitian S. Jiang, Tingting T. Li, Yingxue Y. Jin, Zhiqiang Z. Wang
Journal: Journal of Medicinal Chemistry
Year: 2024

2️⃣ Enhanced Catalytic Activity of Fe3O4-Carbon Dots Complex in the Fenton Reaction for Enhanced Immunotherapeutic and Oxygenation Effects

Authors: Guanghao G. Li, Yujun Y. Bao, Hui H. Zhang, Zhiqiang Z. Wang, Yingxue Y. Jin
Journal: Journal of Colloid and Interface Science
Year: 2024

3️⃣ A Novel Nanomedicine Integrating Ferroptosis and Photothermal Therapy, Well-Suitable for PD-L1-Mediated Immune Checkpoint Blockade

Authors: Yujun Y. Bao, Guanghao G. Li, Siqi S. Li, Changhong C. Guo, Yingxue Y. Jin
Journal: Materials Today Bio
Year: 2024

4️⃣ Targeted Delivery of Rhein via Hyaluronic Acid Modified Liposomes for Suppression of Growth and Metastasis of Breast Cancer

Authors: Jingchun J. Wang, Dijing D. Fan, Defu D. Cai, Yingxue Y. Jin
Journal: International Journal of Biological Macromolecules
Year: 2024

5️⃣ DFT-Aided Stereo-Structural and Electronic Structure Studies of Poly-Hydroxyl Substituted Chlorophyllous Molecules

Authors: Xiong X. Zhang, Tingting T. Li, Qi Q. Wang, Wen W. Fang, Zhiqiang Z. Wang
Journal: Computational and Theoretical Chemistry
Year: 2024

Donglin Sun | Prostate Cancer | Best Researcher Award

Posted on 17/03/202517/03/2025 by Pencis

Dr. Donglin Sun | Prostate Cancer | Best Researcher Award

Southern Medical University | China

AUTHOR PROFILE

Scopus

🔬SUN DONGLIN – MEDICAL DOCTOR IN ONCOLOGY

📚EARLY ACADEMIC PURSUITS

Sun Donglin began his academic journey at No.1 Middle School of Fuyang, Anhui Province (2005-2008). His strong foundation in science led him to pursue a Bachelor’s Degree in Clinical Medicine at Bengbu Medical College (2008-2013), where he developed a keen interest in oncology. His dedication and passion for medical research culminated in a PhD in Oncology through the Master-Doctor Continuous Program at the Affiliated Cancer Hospital of Guangzhou Medical University (2018-2023). He was recognized as an “Outstanding Graduate Student” and “Excellent Graduate”, a testament to his academic excellence and research contributions.

🏥PROFESSIONAL ENDEAVORS

Sun Donglin’s clinical training and professional career reflect a steady progression in expertise:

2013 – 2016: Surgical Resident, Third Affiliated Hospital of Sun Yat-sen University – Gained hands-on experience in surgical oncology.
2016 – 2018: Urology Resident Physician, Shenzhen Hospital of Southern Medical University – Developed a specialization in urological oncology.
2023 – Present: Urology Associate Chief Physician, Shenzhen Hospital of Southern Medical University – Achieved Associate Chief Physician Certification in 2020, demonstrating his leadership in urologic oncology and clinical excellence.

🔍RESEARCH FOCUS

Sun Donglin’s research focuses on two critical areas in oncology:

Mechanisms of Non-Canonical NF-κB Signaling in Renal Fibrosis – Investigating how alternative pathways of NF-κB contribute to fibrosis, which has significant implications for kidney disease treatments.
Drug Resistance Mechanisms in Prostate Cancer – Exploring molecular resistance pathways in prostate cancer to enhance therapeutic strategies and overcome treatment barriers.

💡CONTRIBUTIONS TO SCIENTIFIC RESEARCH

Sun Donglin has led and participated in several high-impact research projects:

Principal Investigator:
- National Natural Science Foundation of China (Youth Program) – 300,000 RMB (2025-2027) (Approval No.: 82400789)
- Guangdong Provincial Medical Science and Technology Research Fund – 10,000 RMB (2024-2026) (Approval No.: A2024317)
- Southern Medical University National Natural Science Foundation Cultivation Program – 100,000 RMB (2024-2026) (Approval No.: 23H3AGZR02)
Key Participant in Major Research Projects:
- National Natural Science Foundation of China Major Research Program Cultivation Project – 680,000 RMB (2020-2022) (Approval No.: 91949102)
- National Natural Science Foundation of China General Program – 570,000 RMB (2019-2022) (Approval No.: 81874095)

🌍IMPACT AND INFLUENCE 🌍

Sun Donglin’s research has contributed to a deeper understanding of renal fibrosis mechanisms and drug resistance in prostate cancer. His work has the potential to improve therapeutic interventions and patient outcomes, particularly in treatment-resistant prostate cancer cases. His collaborations in major national projects highlight his role as an emerging leader in oncological research.

🏅ACADEMIC CITES AND RECOGNITION

Recognized as an Outstanding Graduate Student and Excellent Graduate during his PhD.
His research findings are gaining recognition in top-tier oncology journals, further solidifying his influence in the field.
Contributions to multi-million RMB-funded research projects, showcasing his ability to secure competitive grants.

🌱LEGACY AND FUTURE CONTRIBUTIONS

Sun Donglin’s work will shape the future of oncology therapeutics and urological oncology. His research on non-canonical NF-κB signaling could unlock new pathways for renal fibrosis treatment, while his studies on prostate cancer drug resistance could lead to novel therapeutic strategies.

Moving forward, he aims to:
✅ Expand research collaborations internationally to enhance the impact of his studies.
✅ Develop translational therapies targeting NF-κB signaling in fibrosis and prostate cancer.
✅ Mentor young oncologists and researchers to foster the next generation of medical scientists.

🌍CONCLUSION

Dr. Sun Donglin is a rising leader in oncology research and urological oncology, with a strong foundation in both clinical practice and scientific innovation. His expertise in non-canonical NF-κB signaling in renal fibrosis and drug resistance in prostate cancer has positioned him as a key contributor to the advancement of cancer therapeutics.

📊🔬NOTABLE PUBLICATION:

Title: Serum RelB is correlated with renal fibrosis and predicts chronic kidney disease progression
Authors: Sun, D., Xie, N., Wang, X., Wu, W., Li, X. Y., Chen, X., Qian, G., Li, C., Zhang, H., Jiang, Y., Ye, D., Liu, D., Hu, Y., Wang, J., Chen, W., Zhao, Q., Zeng, M., Zhang, J., Wang, L., & Zhang, X
Journal: Clinical and Translational Medicin
Year: 2021

Title: B-cell-derived IL-10 promotes allergic sensitization in asthma regulated by Bcl-3.
Authors: Qian, G., Jiang, W., Sun, D., Sun, Z., Chen, A., Fang, H., Wang, J., Liu, Y., Yin, Z., Wei, H., Fang, H., & Zhang, X.
Journal: Cellular & Molecular Immunology
Year: 2023

Title: Development of RelB-Targeting Small Molecule Inhibitors of Non-canonical NF-κB Signaling with Antitumor Efficacy
Authors: Li, C., Wei, S., Sun, D., Yang, Z., Wang, Q., Lin, H., Zhang, H., Hu, Y., Liu, D., Ye, D., Tao, Y., Liu, Z., Xu, Z., Li, B., Li, L., Zhang, J., Chen, X., Xie, N., Shi, Y., Liu, S., Liu, Y., Jiang, Y., Zhu, W., & Zhang, X.
Journal: Molecular Therapy
Year: 2025

Title: LKB1 activated by NaB inhibits the IL-4/STAT6 axis and ameliorates renal fibrosis through the suppression of M2 macrophage polarization.
Authors: Liang, W., Wu, H., Long, Q., Lin, H., Lv, X., Ma, W., Wu, T., Ai, L., Zheng, Q., Guo, J., Chen, X., Guo, J., & Sun, D..
Journal: Life Sciences
Year: 2025

Title: Integrative analysis of potential diagnostic markers and therapeutic targets for glomerulus-associated diabetic nephropathy based on cellular senescence
Authors: Sun, D., Wei, S., Wang, D., Zeng, M., Mo, Y., Li, H., Liang, C., Li, L., Zhang, J. W., & Wang, L
Journal: Frontiers in Immunology
Year: 2023

yuchang li | Chinese Medicine | Best Researcher Award

Posted on 15/03/202515/03/2025 by Pencis

Mr. yuchang li | Chinese Medicine | Best Researcher Award

Shanxi University of Chinese Medicine | China

AUTHOR PROFILE

ORCID ID

🎓 EARLY ACADEMIC PURSUITS

Yu-chang Li is currently a student at Shanxi University of Chinese Medicine, enrolled in the Third Clinical College of Clinical Medicine, specializing in Traditional Chinese and Western Medicine. From an early stage in his academic journey, he has demonstrated a strong passion for integrating traditional Chinese medicine (TCM) with modern medical approaches. His commitment to research and academic excellence has been recognized through numerous awards and publications.

🏆 PROFESSIONAL ENDEAVORS

Yu-chang Li has made significant contributions to medical research, particularly in the field of oncology alternative medicine. His work bridges the gap between traditional Chinese medicine and Western medical practices, exploring innovative therapeutic approaches to combat life-threatening diseases.

His achievements include:
✅ Winner of multiple prestigious awards, including:

National Silver Award at the 10th National College Students Basic Medical Innovation Research and Experimental Design Forum
Provincial Silver Award
Provincial Bronze Award

✅ Published two SCI-indexed research papers, demonstrating expertise in oncology and alternative medicine.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CHINESE MEDICINE

Yu-chang Li’s research is centered on the role of Chinese herbal medicine in oncology, with a particular focus on the immunomodulatory effects of Astragalus membranaceus (Huangqi) and other herbal formulations.

🔹 Astragalus Injection and Osteosarcoma
One of his landmark studies, Astragalus Injection Inhibits the Growth of Osteosarcoma by Activating Cytotoxic T Lymphocyte and Targeting CTSL, investigates the use of Huangqi Injection (HQI) in treating osteosarcoma. His research highlights the immunomodulatory potential of HQI, demonstrating that its active component, Cycloastragenol (CG), enhances immune response and targets CTSL, leading to tumor suppression.

🔹 Shenqi Granules and Cerebral Ischemia-Reperfusion Injury
In another study, Shenqi Granules Enhance Recovery from Cerebral Ischemia-Reperfusion Injury by Modulating Tryptophan and Tyrosine Metabolism and Activating NFE2L2/NRF2, he explores the neuroprotective effects of Shenqi granules. His findings contribute to stroke rehabilitation research, emphasizing the potential of herbal formulations in neurological recovery.

His research provides scientific validation for traditional Chinese medicine (TCM) therapies, paving the way for their integration into modern medical treatments.

🌍 IMPACT AND INFLUENCE

Yu-chang Li’s research has had a profound impact on both oncology and alternative medicine by:
📌 Advancing integrative medicine through scientific validation of herbal treatments.
📌 Contributing to cancer immunotherapy using TCM-based approaches.
📌 Providing new perspectives on the treatment of osteosarcoma and stroke recovery.
📌 Inspiring future researchers to explore synergistic applications of Chinese and Western medicine.

📖 ACADEMIC CITATIONS AND RECOGNITION

As a young scholar, Yu-chang Li’s publications have gained recognition in the scientific community, contributing valuable insights to the fields of Chinese medicine and oncology. His work is frequently cited by researchers investigating herbal immunotherapy, oncology treatments, and neuroprotection strategies.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Yu-chang Li is poised to become a leading figure in integrative medicine, focusing on oncology and alternative therapies. His future contributions may include:
✨ Developing new herbal formulations for cancer treatment.
✨ Conducting clinical trials to further validate TCM therapies.
✨ Bridging the gap between traditional and modern medicine.
✨ Expanding the global acceptance of TCM in cancer care.

His research and innovations will undoubtedly shape the future of medicine, providing safe, effective, and scientifically backed treatments that integrate the wisdom of traditional Chinese medicine with modern scientific advancements.

🌍CONCLUSION

Yu-chang Li is a rising scholar in integrative medicine, dedicated to advancing the scientific understanding of Traditional Chinese Medicine (TCM) and its applications in oncology and neurological disorders. His research on Astragalus Injection in osteosarcoma and Shenqi granules in stroke recovery showcases the therapeutic potential of herbal medicine, reinforcing the importance of evidence-based alternative treatments.

📊🔬NOTABLE PUBLICATION:

Title: Shenqi granules enhance recovery from cerebral ischemia-reperfusion injury by modulating tryptophan and tyrosine metabolism and activating NFE2L2/NRF2.
Authors: Liu HX, Yang MK, Li YC, Liu CX, Li GP, Meng XL, Pei K, Wen SY
Journal: International Journal of Phytotherapy and Phytopharmacology
Year: 2025

Title: Astragalus injection inhibits the growth of osteosarcoma by activating cytotoxic T lymphocyte and targeting CTSL.
Authors: Liu HX, Li YC, Su RB, Liu CX, Wen SY.
Journal: Journal of Ethnopharmacology
Year: 2025